Pharmakologische Langzeitbehandlung schizophrener Erkrankungen

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Der Nervenarzt

• Publication date

  2014-03-02

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00115-013-3807-7PMID 24603949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kompendium der Psychiatrischen Pharmakotherapie

  2017cited by this paper
• Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

  2013cited by this paper
• Adverse Effects Associated with Second‐Generation Antipsychotic Long‐Acting Injection Treatment: A Comprehensive Systematic Review

  2013cited by this paper
• Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.

  2013cited by this paper
• Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials

  2013cited by this paper
• Schizophrenie – eine einheitliche Krankheit?

  2013cited by this paper
• Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.

  2013cited by this paper
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects

  2013cited by this paper
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

  2013cited by this paper
• Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.

  2012cited by this paper
• Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis.

  2012cited by this paper
• Augmentation of clozapine with a second antipsychotic – a meta‐analysis

  2012cited by this paper
• Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review.

  2012cited by this paper
• Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).

  2012cited by this paper
• Brief Psychiatric Rating Scale - Excited Component (BPRS-EC) and neuropsychological dysfunction predict aggression, suicidality, and involuntary treatment in first-episode psychosis.

  2012cited by this paper
• Effects of Psychoactive Substances in Schizophrenia – Findings of Structural and Functional Neuroimaging

  2012cited by this paper
• Effects of psychoactive substances in schizophrenia -- findings of structural and functional neuroimaging.

  2012cited by this paper
• Recovery from schizophrenia: form follows functioning

  2012cited by this paper
• Considering DSM-5: Personality Diagnostics in Patients with Schizophrenia Spectrum Disorders

  2012cited by this paper
• When Psychopharmacology Is Not Enough: Using Cognitive Behavioral Therapy Techniques for Persons with Persistent Psychosis

  2011cited by this paper
• Differential 3-Year Effects of First- Versus Second-Generation Antipsychotics on Subjective Well-Being in Schizophrenia Using Marginal Structural Models

  2011cited by this paper
• Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial

  2011cited by this paper
• Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.

  2011cited by this paper
• Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia.

  2011cited by this paper
• A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.

  2011cited by this paper
• Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years

  2011cited by this paper
• Assertive community treatment as part of integrated care versus standard care: a 12-month trial in patients with first- and multiple-episode schizophrenia spectrum disorders treated with quetiapine immediate release (ACCESS trial).

  2010cited by this paper
• The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

  2010cited by this paper
• The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

  2009cited by this paper
• Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature.

  2009cited by this paper
• 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

  2009cited by this paper
• The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

  2009cited by this paper
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years.

  2008cited by this paper
• Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors.

  2008cited by this paper
• Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort.

  2008cited by this paper
• Management of incomplete remission and treatment resistance in first-episode psychosis.

  2008cited by this paper
• Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors

  2008cited by this paper
• Rates and predictors of remission and recovery during 3 years in 392 never‐treated patients with schizophrenia

  2008cited by this paper
• Management of incomplete remission and treatment resistance in first-episode psychosis

  2008cited by this paper
• Schizophrenia: a concise overview of incidence, prevalence, and mortality.

  2008cited by this paper
• Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications.

  2007cited by this paper
• Understanding and addressing adherence issues in schizophrenia: from theory to practice.

  2007cited by this paper
• Monitoring and managing weight gain in the mentally ill.

  2007cited by this paper
• Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study

  2006cited by this paper
• Komorbide psychische Störungen bei Schizophrenie

  2006cited by this paper
• Komorbidität Psychose und Sucht — was tun?

  2006cited by this paper
• Pharmakotherapie der Schizophrenie

  2006cited by this paper
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• 6 Pharmakotherapie der Schizophrenie

  2004cited by this paper
• Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative.

  2004cited by this paper
• Komorbidität Psychose und Sucht

  2003cited by this paper
• Chlorpromazine equivalent doses for the newer atypical antipsychotics.

  2003cited by this paper
• First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.

  2002cited by this paper
• Vocational rehabilitation for persons with schizophrenia: recent research and implications for practice.

  2000cited by this paper
• Compliance with medication regimens for mental and physical disorders.

  1998cited by this paper
• The current unsatisfactory state of relapse prevention in schizophrenic psychoses--suggestions for improvement.

  1991cited by this paper
• The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome.

  1984cited by this paper

• Compulsory psychiatric admissions in the canton of Basel-Stadt between September 2013 and April 2022: Analysis of the cantonal database of the Health Department of Basel-Stadt

  2022cites this paper
• Die Haltung der Öffentlichkeit zu Zwangsmassnahmen bei psychiatrischen PatientInnen

  2022cites this paper
• Approval of Coercion in Psychiatry in Public Perception and the Role of Stigmatization

  2022cites this paper
• Psychoedukation bei schizophrenen Psychosen: State of the art

  2020cites this paper
• Psychoedukation und Angehörigenarbeit bei Schizophrenie

  2020cites this paper
• Could Animal-Assisted Therapy Help to Reduce Coercive Treatment in Psychiatry?

  2019cites this paper
• Sechs Jahre „offene Türen“ an den Universitären Psychiatrischen Kliniken Basel

  2019cites this paper
• [Quality of life as a target criterion in schizophrenia therapy].

  2018cites this paper
• Einfluss einer „Offenen-Tür-Politik“ auf die Stationsatmosphäre: Auswirkungen auf die Behandlungsqualität

  2017cites this paper
• Antipsychotika-Depotbehandlung im Wandel der Zeit

  2016influential citation
• Reduction of seclusion on a hospital-wide level: successful implementation of a less restrictive policy.

  2014cites this paper
• Zentraler Knotenpunkt im psychotherapeutischen Behandlungsnetz

  2014cites this paper